Get the Stockscreener App
7.52
0.40%
0.03
After Hours:
7.52
Trevi Therapeutics Inc stock is traded at $7.52, with a volume of 895.35K.
It is up +0.40% in the last 24 hours and up +9.62% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$7.49
Open:
$7.56
24h Volume:
895.35K
Relative Volume:
0.49
Market Cap:
$882.04M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-25.93
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
+1.35%
1M Performance:
+9.62%
6M Performance:
+84.77%
1Y Performance:
+173.45%
1-Day Range:
$7.37
$7.57
1-Week Range:
$7.055
$7.655
52-Week Range:
$2.36
$8.11
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.52 | 912.11M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trendline Breach Raises Concern for Trevi Therapeutics Inc. InvestorsInsider Buying & Community Shared Stock Ideas - 선데이타임즈
Is This the Dip to Buy in Trevi Therapeutics Inc.Portfolio Risk Summary & Reliable Intraday Trade Alerts - classian.co.kr
Trevi Therapeutics: Optimism Amid Earnings Call Insights - MSN
Healthcare Analysts Offer Insights on Trevi Therapeutics, DENTSPLY SIRONA, and Arrowhead Pharmaceuticals. - AInvest
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionForward PE Discount Stocks - classian.co.kr
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $22.00 at Needham & Company LLC - MarketBeat
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data - MSN
Trevi Therapeutics' Promising Developments and Strategic Expansion Bolster Growth Potential. - AInvest
Trevi Therapeutics' Path to Sustainable Growth and Value Creation - AInvest
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans - uk.finance.yahoo.com
Trevi Therapeutics (TRVI): A High-Potential Biotech Play in Chronic Cough with a Clear Path to Phase 3 and FDA Alignment - AInvest
Trevi Therapeutics Gears Up For Next Phase After Positive Results - Finimize
Summit Therapeutics shares rise 1.53% intraday after Trevi Therapeutics reports positive Phase 2b trial results for Haduvio. - AInvest
Unlocking Long-Term Value: Trevi Therapeutics' Strategic Capital Efficiency and Robust Clinical Data Drive Phase III Momentum - AInvest
Transcript : Trevi Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics - TipRanks
Earnings call transcript: Trevi Therapeutics Q2 2025 shows slight EPS beat - Investing.com Australia
Trevi Therapeutics Inc (TRVI) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Trevi Therapeutics Inc (TRVI) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Trevi Therapeutics Reports Positive Trial Results and Financial Stability - TipRanks
Trevi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Trevi Therapeutics Q2 EPS beats estimates - MarketScreener
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - PR Newswire
Trevi Therapeutics TRVI Q2 2025 Earnings Preview Upside Potential with Positive Share Dynamics - AInvest
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 - 富途牛牛
Is Trevi Therapeutics Inc. stock overvalued or undervaluedMassive profits - Jammu Links News
Should I hold or sell Trevi Therapeutics Inc. stock in 2025Free Investment Timing Strategies - Jammu Links News
What is the risk reward ratio of investing in Trevi Therapeutics Inc. stockUnlock daily stock market insights for success - Jammu Links News
What makes Trevi Therapeutics Inc. stock price move sharplyFree Market Dynamics Reports - Jammu Links News
Published on: 2025-08-03 17:59:19 - Jammu Links News
When is Trevi Therapeutics Inc. stock expected to show significant growthFree Buy/Sell Signal Notifications - Jammu Links News
How strong is Trevi Therapeutics Inc. company’s balance sheetUnlock powerful trading alerts for success - Jammu Links News
What analysts say about Trevi Therapeutics Inc. stockUnlock rapid growth potential in your portfolio - Jammu Links News
Why is Trevi Therapeutics Inc. stock attracting strong analyst attentionExceptional market performance - Jammu Links News
What institutional investors are buying Trevi Therapeutics Inc. stockMarket Forecast Recommendation With Low Risk - Jammu Links News
Trevi Therapeutics to Report Second Quarter 2025 Financial Resul - GuruFocus
Trevi Therapeutics Q2 Earnings: Key Updates on Chronic Cough Drug Trials Coming August 7 - Stock Titan
Is it the right time to buy Trevi Therapeutics Inc. stockEntry Signal Growth Plan For Every Investor - Jammu Links News
Trend analysis for Trevi Therapeutics Inc. this weekLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Has Trevi Therapeutics Inc. formed a bullish divergenceFundamental + Technical Combined Watchlist - Newser
Predicting Trevi Therapeutics Inc. trend using moving averagesRisk Balanced Picks for Safer Trading - Newser
Bullish Candlestick Pattern Forms in Trevi Therapeutics Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
Developing predictive dashboards with Trevi Therapeutics Inc. dataDaily Market Entry Strategy with Tools - Newser
Trevi Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Hot Stocks Based on Volume Flow - Newser
Trevi Therapeutics Inc.’s Beta Climbs After Market VolatilityAI Screening for Swing Trade Picks Finds Momentum - metal.it
Why did Trevi Therapeutics' operating expenses surge in Q3 2024? - AInvest
Trevi Therapeutics to Participate in Upcoming August Conferences - PR Newswire
Trevi Therapeutics Leadership Showcases Chronic Cough Treatment Progress at Major August Biotech Conferences - Stock Titan
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):